Science

To help our patients, GB Sciences is creating a pipeline for the development of novel medicines based on our own patent-pending formulations of chemicals extracted from the Cannabis plant. Through its wholly-owned subsidiary, Growblox Life Sciences, LLC, GB Sciences has now filed three provisional patent applications on new therapies that are complex mixtures of compounds derived from cannabis, and it has licensed an additional approved patent.

GB Sciences partners with universities and contract research organizations (CROs), who bring both expertise and infrastructure at a reasonable cost to our program. Our end goal is not to take these novel formulations to market ourselves, because we know our limitations. Our goal is to be the perfect partner to those companies with greater resources and experience in the marketing and distribution of medications worldwide.

GB Sciences’ Competitive Advantages

GB Sciences has several advantages over both pharmaceutical companies and academic researchers when it comes to the discovery and validation of new drug formulations from cannabis-derived compounds.

GB Sciences’ Patient Groups

Through its wholly-owned subsidiary, Growblox Life Sciences, LLC, GB Sciences has filed three provisional patent applications containing formulations to tackle the following conditions.

Biopharma Pipeline

GB Sciences has several advantages over both pharmaceutical companies and academic researchers when it comes to the discovery and validation of new drug formulations from cannabis-derived compounds.

Research Partners

Through its wholly-owned subsidiary, Growblox Life Sciences, LLC, GB Sciences has filed three provisional patent applications containing formulations to tackle the following conditions.

Bitnami